Voyager Limited Liability Company
Mark Kay is a leading researcher in the fields of gene therapy and AAV biology, including the identification of new AAV capsids. Dr. Kay is the Head of the Division of Human Gene Therapy, and professor in the departments of pediatrics and genetics at Stanford University School of Medicine. He is one of the founders of the American Society of Gene and Cell Therapy, served as its president from 2005 to 2006, and was the recipient of the society’s Outstanding Investigator Award in 2013. Dr. Kay received the E. Mead Johnson Award for Research in Pediatrics in 2000. He was elected to the American Society for Clinical Investigation in 1997 and the Association for American Physicians in 2010. He has organized many national and international conferences, including the first Gordon Conference related to gene therapy. Dr. Kay is respected worldwide for his work in vector development, gene therapy for hemophilia and viral hepatitis, and non-coding RNA biology. He is currently the Editor of Human Gene Therapy and serves on the editorial boards of other peer-reviewed publications.